Simple Science

Cutting edge science explained simply

# Health Sciences # Infectious Diseases (except HIV/AIDS)

COVID-19: Gender Differences in Risks and Effects

Examining how COVID-19 impacts men and women differently.

Shelli R. Kesler, Alexa De La Torre Schutz, Oscar Y. Franco Rocha, Kimberly Lewis

― 5 min read


COVID-19 Gender Effects COVID-19 Gender Effects differently. Men and women experience COVID-19
Table of Contents

COVID-19 has been a topic of discussion for a while, and it turns out that it doesn't treat everyone equally. Studies show that men seem to face greater risk of severe outcomes compared to women. But why is that? Let's break it down in simple terms, without all the scientific mumbo jumbo.

The Role of Certain Proteins

COVID-19 enters our bodies through specific proteins called ACE2 and TMPRSS2. Think of these proteins as the "doorbells" that the virus rings to get inside our cells. Men tend to have higher levels of these doorbells in their bodies. So, when COVID-19 comes knocking, men may have more access than women, which could explain the higher mortality rates.

But wait, there's more! Another protein, HLA-DQA2, may also play a role in how long someone stays sick after catching COVID-19. This protein helps our immune system recognize troublemakers, aka viruses. There isn’t much research on how this protein behaves differently in men and women, but we know that sex can affect how our immune systems work.

Long COVID: The Unwanted Guest

Now, even after the main show is over, some people might feel lingering effects from COVID-19-often referred to as "long COVID." These can include various symptoms like brain fog, which is a fancy way of saying you feel fuzzy-headed. Strangely enough, studies suggest that women are more likely to experience long COVID symptoms, even though men have a higher chance of severe illness.

Brain Changes After COVID-19

Researchers have discovered that COVID-19 can cause changes in the brain, even for those who had mild cases. Some studies show that this can include changes in areas of the brain responsible for memory and cognition. And while men may face higher risks of dying from COVID-19, women seem to report more issues like brain fog and other neurological problems afterward.

What Happens in the Brain?

So, what happens to these proteins in the brain? ACE2 levels appear to be out of whack in individuals who have had COVID-19, especially those with noticeable neurological issues. Although we don’t know much about TMPRSS2 in the brain, recent findings suggest that both ACE2 and TMPRSS2 show up in similar brain areas, signaling they might be teaming up in brain functions.

There’s also some indication that proteins like HLA-DQA2 can come into play when our brain is on high alert due to inflammation, which can happen after an infection. Unfortunately, too much inflammation isn’t good for the brain and can make existing problems worse, like in cases of diseases such as Alzheimer’s and multiple sclerosis.

What Do the Numbers Say?

There’s exciting evidence from certain studies exploring gene expression in tissues from men and women. Most of the research indicates that ACE2 levels are generally higher in men than in women. However, there isn’t much on TMPRSS2 and HLA-DQA2. Some studies found no significant differences in TMPRSS2 across various organs, but again, they didn't check the brain.

The Good, the Bad, and the Brain

So, we have all these proteins affecting how people experience COVID-19, but there’s still a lot we don’t know. It’s like trying to interpret a song you don’t fully understand. While researchers discovered that men have higher levels of certain proteins, that doesn’t automatically mean they’ll have more problems. Women might experience more neurological symptoms due to various reasons, including better immune responses that can sometimes backfire, leading to higher inflammation.

Plus, there could be a difference in how symptoms are reported. Women are more likely to express their symptoms, while healthcare providers may put more weight on what women say compared to men. This could skew the numbers.

A Peek into Studies

Various studies have looked at cognitive function after COVID-19 and have reported mixed results. Some found that women showed lower cognitive performance, while others didn’t see much difference. It's a bit like flipping a coin-sometimes it shows heads, sometimes tails.

To make matters worse, there aren’t many studies that specifically look into whether men or women are more affected by long COVID. Most research focuses on general symptoms instead of digging deep into what might be going on with different sexes.

Moving Forward: What’s Next?

The data suggests that there’s a connection between ACE2, TMPRSS2, and HLA-DQA2 and how they work together in our Brains. This connection may play a role in how severe COVID-19 symptoms can be and why recovery can vary between men and women.

Researchers are now interested in studying other proteins and how they interact with the COVID-19 genes. One area to pay attention to is the role of MHC Class II molecules in the brain because they may be involved in how the brain reacts to various diseases.

Final Thoughts: The Mystery Continues

In a nutshell, we’re still figuring out the puzzle of how COVID-19 affects men and women differently. The information we have is only scratching the surface. Although it’s clear that biological differences, especially regarding certain proteins, lead to different outcomes, the bigger picture is intertwined with many variables.

With ongoing studies, we hope to get a clearer picture of how COVID-19 interacts with sex differences, immune responses, and brain health. After all, knowledge is power, and who wouldn’t want to have more power over this pesky virus?

Original Source

Title: Sex differences in ACE2, TMPRSS2, and HLA-DQA2 expression in gray matter: Implications for post-COVID-19 neurological symptoms

Abstract: COVID-19 has been associated with sex differences in terms of mortality and morbidity. Viral entry proteins including those regulated by ACE2 and TMPRSS2 may play a role, but few studies have been conducted to date and none have examined sex differences in brain expression. Additionally, HLA-DQA2 expression has emerged as a potential moderator of COVID-19 outcomes. Using non-invasive imaging transcriptomics, we measured ACE2, TMPRSS2, and HLA-DQA2 mRNA expression in gray matter volumes using MRI scans obtained from 1,045 healthy adults aged 21-35 years (44% male) imaged prior to the COVID-19 pandemic. ACE2 (t = 9.24, p < 0.001, d = 0.576), TMPRSS2 (t = 24.66, p < 0.001, d = 1.54), and HLA-DQA2 (t = 3.70, p < 0.001, d = 0.231) expression was significantly higher in males compared to females. Bayesian network analysis indicated significant (p < 0.05) positive causal paths from ACE2 to HLA-DQA2 (B = 0.282), ACE2 to TMPRSS2 (B = 0.357), and TMPRSS2 to HLA-DQA1 (B = 0.139) and a negative causal path from sex (males = -1, females = 1) to TMPRSS2 (B = -0.607). Our results have important implications for neurological symptoms associated with COVID-19 and long COVID including complex interactions between viral entry proteins and immune responses, sex-related disparities in symptom reporting and diagnosis, assessment of neurological problems after COVID-19, and potential COVID-19 related syndemics. However, further research is needed to determine gene expression patterns by sex and COVID-19 outcomes, to evaluate additional genes that may influence neurologic status, and studies that include objective assessments of neurologic outcomes.

Authors: Shelli R. Kesler, Alexa De La Torre Schutz, Oscar Y. Franco Rocha, Kimberly Lewis

Last Update: 2024-11-04 00:00:00

Language: English

Source URL: https://www.medrxiv.org/content/10.1101/2024.11.04.24316706

Source PDF: https://www.medrxiv.org/content/10.1101/2024.11.04.24316706.full.pdf

Licence: https://creativecommons.org/licenses/by-nc/4.0/

Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.

Thank you to medrxiv for use of its open access interoperability.

Similar Articles